Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualing Pharmaceutical-B, and others [3]. Core Insights - The pharmaceutical sector has outperformed the market, with a focus on the potential of innovative drugs and the CD73 target in cancer immunotherapy [4][5]. - The report highlights the promising clinical progress of CD73 inhibitors, with several products in various stages of clinical trials [21][25]. Summary by Sections Industry Investment Rating - The report provides a list of recommended companies with "Buy" and "Hold" ratings, indicating strong investment potential in the pharmaceutical sector [3]. Industry Performance - The pharmaceutical sector rose by 1.13%, outperforming the CSI 300 index by 0.25 percentage points, with innovative drugs and vaccines leading the performance [5][32]. Company Dynamics - Companies such as Lepu Medical and Sunshine Nuohua have made significant announcements regarding new product approvals and clinical trial progress, indicating a robust pipeline and growth potential [33][34]. Industry Trends - The report discusses the increasing focus on innovative drugs and the impact of regulatory changes on the pharmaceutical landscape, suggesting a shift towards high-efficiency business models in the industry [31][40].

Group 1: CD73 and Cancer Immunotherapy - CD73 is a promising target for cancer immunotherapy, acting as a rate-limiting enzyme in the production of extracellular adenosine, which has immunosuppressive effects in various diseases [1] - CD73 is overexpressed in the tumor microenvironment (TME) of several cancer types, including breast cancer, melanoma, and lung cancer, and plays a significant role in immune regulation [1] - Several products targeting CD73 are in clinical research, with leading small molecule inhibitors being Arcus's AB680 and Deqi's ATG-037, while monoclonal antibodies like AstraZeneca's Oleclumab and Tianjing's Uliledlimab have entered Phase 3 trials [1] Group 2: Pharmaceutical Sector Performance - The pharmaceutical sector rose by 1.13%, outperforming the CSI 300 index by 0.25 percentage points, with innovative drugs, vaccines, and medical packaging performing relatively well [1] - The investment strategy suggests focusing on the impact of market pricing power and capital changes, particularly in AI healthcare and innovative drugs [1] - The domestic dual-antibody ADCs, TYK2 inhibitors, GKA agonists, and pan-KRAS inhibitors are considered globally leading pipelines, with recommended companies including Innovent Biologics, Baiyi Tianheng, and others [1] Group 3: API Market Dynamics - From 2025 to 2030, the sales impact of expiring formulation patents is projected to be $390 billion, a 124% increase compared to the total from 2019 to 2024, indicating a significant demand for APIs [2] - In 2024, the output of APIs in large-scale industrial enterprises is expected to reach 3.583 million tons, a 4.6% year-on-year increase, with Q2 and Q3 showing substantial growth [2] - India's imports of APIs and intermediates from China are projected to reach 3.4 billion yuan in 2024, with a rapid growth in import volume, indicating a recovery in the API industry [2] Group 4: CXO Sector Insights - The Federal Reserve's dovish stance is expected to lead to increased liquidity, with predictions of rate cuts in 2025 and 2026, which may shift investment preferences towards undervalued sectors like pharmaceuticals [3] - The recovery in overseas investment and domestic innovative drug performance is anticipated to improve local financing conditions, with a projected $58.2 billion in global healthcare financing in 2024 [3] - The demand for CXO services is expected to improve as overseas orders recover, positively impacting performance in the sector [3] Group 5: Company Recommendations - Companies benefiting from domestic innovative drug support policies include clinical CROs like Sunshine Nuohe and Nuosige, while life science upstream companies like Haoyuan Pharmaceutical are expected to benefit from overseas business recovery [4] - The generics sector is poised for growth due to policy changes, with recommendations for companies with rich pipelines and high efficiency, such as Kelun Pharmaceutical and Yifan Pharmaceutical [4]

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Tianfang Pharmaceutical, has received a drug registration certificate for Clopidogrel Hydrogen Sulfate Tablets, which is expected to enhance the company's cardiovascular medication product line and provide valuable experience for future generic drug development [1][6]. Group 1: Drug Registration Information - The drug name is Clopidogrel Hydrogen Sulfate Tablets, with a specification of 75mg [1]. - The registration application was accepted by the National Medical Products Administration (NMPA) in January 2024 [3]. - The total investment in the drug development has reached approximately 19.54 million RMB (about 2.95 million USD) [4]. Group 2: Market Situation - As of the announcement date, 21 other companies, including Shijiazhuang Yiling Pharmaceutical, Shenzhen Mindray Bio-Medical Electronics, and Zhejiang Jingxin Pharmaceutical, have also obtained production licenses for this drug [5]. - Clopidogrel Hydrogen Sulfate Tablets are classified as a Category B drug under the medical insurance system, with total domestic sales of approximately 4.924 billion RMB (about 0.74 billion USD) in 2023 and projected sales of about 5.376 billion RMB (about 0.81 billion USD) in 2024 [5].

证券代码：002020 证券简称：京新药业 公告编号：2025034 浙江京新药业股份有限公司 关于股份回购进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、回购股份方案的基本情况 浙江京新药业股份有限公司(以下简称"公司")于 2025 年 1 月 8 日召开的 第八届董事会第十二次会议，审议通过了《关于股份回购的方案》，公司使用自 有资金以集中竞价交易方式回购公司股份，回购的公司股份将用于股权激励或员 工持股计划。本次回购总金额为不低于人民币 20,000 万元(含)，不超过人民币 40,000 万元（含），回购价格不超过 14.80 元/股（含），若按回购总金额上、 下限和回购股份价格上限测算，预计回购股份数量约为 1,351 万股-2,703 万股， 约占目前公司总股本的 1.57%-3.14%。具体回购金额及回购数量以回购完成时实 际使用的资金和回购的股份数量为准。回购股份的实施期限自董事会审议通过本 次回购股份方案之日起 12 个月内。具体内容详见公司于 2025 年 1 月 9 日、2025 年 1 月 10 日 在 《 证 券 时 报 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Viewpoints - The report emphasizes that the ASCO conference has catalyzed enthusiasm for innovative drug investments, with a notable increase in the number of presentations by Chinese experts [3][12] - It is believed that innovative drugs will remain the main focus of pharmaceutical investments in the medium to long term, driven by China's transition from quantity to quality and innovation in drug development, alongside increasing policy support [3][12] - Short-term factors such as US-China tariff disputes and geopolitical tensions may affect overall risk appetite, suggesting a focus on companies that can commercialize large-scale innovative drugs and those in the CXO and life sciences upstream sectors [3][12] Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's weekly return was 2.21%, outperforming the CSI 300 by 3.30%, ranking second among 31 primary sub-industry indices [10] - The chemical pharmaceuticals sub-sector led with a weekly return of 3.83% [10][27] - Over the past month, the sector's return was 6.42%, again ranking second among sub-industry indices [10][17] Industry Dynamics - The report highlights the importance of the ASCO conference held from May 30 to June 3, 2025, in Chicago, which has further stimulated investment interest in innovative drugs [11][12] - The report suggests focusing on the CXO and life sciences upstream sectors, as well as traditional pharmaceutical companies transitioning from generics to innovative drugs [13][14] Recommendations - Companies to watch in the innovative drug chain include Tigermed, WuXi AppTec, and others in the CRO/CDMO space [13] - For the domestic recovery line, companies like Aier Eye Hospital and Tongrentang are recommended [13] - In the self-sufficiency line, high-end medical devices and research instruments from companies like Mindray and Hualan Biological Engineering are highlighted [14] Company-Specific Insights - The report identifies specific companies with strong growth potential, such as Yaoshi Bang, which is expected to achieve a CAGR of approximately 145% in net profit from 2024 to 2027 [15] - Kangchen Pharmaceutical has maintained a net profit growth rate of over 14% for the past three years, with a projected PE of about 8 times in 2025 [15] - Guoyuyuan is expected to see operational improvements in 2025, marking a potential turning point for the company [15][16]

Group 1 - A total of 10 companies will have their restricted shares unlocked today, with a combined volume of 153 million shares and a total market value of 2.094 billion yuan at the latest closing price [3] - The companies with the highest number of unlocked shares are Oufu Egg Industry (13.5 million shares), Shihua Machinery (4.7942 million shares), and Suao Sensor (4.098 million shares) [3] - In terms of market value, Oufu Egg Industry leads with 1.667 billion yuan, followed by Dazhu CNC (149 million yuan) and Yilian Technology (8.03197 million yuan) [3] Group 2 - A total of 30 companies have disclosed their stock repurchase progress, with 31 related announcements made [4] - Six companies have disclosed stock repurchase plans for the first time, while 18 companies have had their repurchase plans approved by shareholders [4] - The companies with the highest proposed repurchase amounts include Jingxin Pharmaceutical (up to 700 million yuan), Haixiang New Materials (50 million yuan), and Aerospace Chuanggu (24.4608 million yuan) [5]

证券代码：002020 证券简称：京新药业 公告编号：2025032 浙江京新药业股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、浙江京新药业股份有限公司（以下简称"公司"）于2025年4月24日召开2024 年度股东大会，审议并通过了《2024年度利润分配方案》的议案。公司2024年度利 润分配方案为：以截止2024年12月31日公司总股本861,029,140 股扣除回购专户上 已回购股份后的股本为基数，按分配比例不变的原则，向全体股东每10股派发现金 红利3.50元（含税），不送红股，不以资本公积金转增股本，剩余未分配利润结转 下一年度。若在分配方案实施前公司总股本由于可转债转股、股份回购、股权激励 行权、再融资新增股份上市等原因而发生变化的，将按照分配比例不变的原则对分 配总额进行相应调整。 2、截至本公告披露日，公司回购专用证券账户持有公司股份47,161,295股,根 据《深圳证券交易所上市公司自律监管指引第9号——回购股份》的相关规定，回购 专用证券账户中的股份不享有利润分配权利，公 ...

Core Viewpoint - Zhejiang Jingxin Pharmaceutical Co., Ltd. has approved a profit distribution plan for the year 2024, which includes a cash dividend of 3.50 yuan per 10 shares for all shareholders, excluding shares held in the company's repurchase account [1][2][3]. Summary by Sections Profit Distribution Plan - The profit distribution plan for 2024 involves a cash dividend of 3.50 yuan per 10 shares, based on a total share capital of 861,029,140 shares, excluding 47,161,295 shares held in the repurchase account [1][2]. - The total cash dividend amount is calculated to be 284,853,745.75 yuan (including tax) [2][4]. - The plan stipulates that if the total share capital changes before the implementation of the distribution due to various reasons, the total distribution amount will be adjusted accordingly while maintaining the distribution ratio [1][2]. Key Dates - The record date for the distribution is set for May 28, 2025, and the ex-dividend date is May 29, 2025 [4]. Dividend Taxation - The cash dividend will be subject to different tax rates based on the holding period of the shares, with specific provisions for different types of shareholders [3][4]. Repurchase Shares - Shares held in the repurchase account will not be entitled to profit distribution rights, and the repurchase price ceiling will be adjusted from 14.80 yuan to 14.47 yuan per share following the distribution [5][6].

证券代码：002020 证券简称：京新药业 公告编号：2025032 浙江京新药业股份有限公司 2024 年年度权益分派实施公告 1、浙江京新药业股份有限公司（以下简称"公司"）于2025年4月24日召开2024 年度股东大会，审议并通过了《2024年度利润分配方案》的议案。公司2024年度利 润分配方案为：以截止2024年12月31日公司总股本861,029,140 股扣除回购专户上 已回购股份后的股本为基数，按分配比例不变的原则，向全体股东每10股派发现金 红利3.50元（含税），不送红股，不以资本公积金转增股本，剩余未分配利润结转 下一年度。若在分配方案实施前公司总股本由于可转债转股、股份回购、股权激励 行权、再融资新增股份上市等原因而发生变化的，将按照分配比例不变的原则对分 配总额进行相应调整。 2、截至本公告披露日，公司回购专用证券账户持有公司股份47,161,295股,根 据《深圳证券交易所上市公司自律监管指引第9号——回购股份》的相关规定，回购 专用证券账户中的股份不享有利润分配权利，公司回购专用证券账户中的回购股份 47,161,295股不参与本次权益分派。因此，公司2024年年度权益分派方案 ...

证券代码：002020 证券简称：京新药业 公告编号：2025033 浙江京新药业股份有限公司 关于调整回购股份价格上限的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、调整前回购股份价格上限：不超过14.80元/股（含）； 2、调整后回购股份价格上限：不超过14.47元/股（含）； 3、回购股份价格上限调整生效日期：2025年5月29日（权益分派除权除息日）。 一、回购股份方案的基本情况 浙江京新药业股份有限公司(以下简称"公司")于2025年1月8日召开的第八届 董事会第十二次会议，审议通过了《关于股份回购的方案》，公司使用自有资金以 集中竞价交易方式回购公司股份，回购的公司股份将用于股权激励或员工持股计 划。本次回购总金额为不低于人民币20,000万元(含)，不超过人民币40,000万元 （含），回购价格不超过14.80元/股（含），若按回购总金额上、下限和回购股份 价格上限测算，预计回购股份数量约为1,351万股-2,703万股，约占目前公司总股 本的1.57%-3.14%。具体回购金额及回购数量以回购完成时实际使用的资金和回购 ...